ADVERTISEMENT
Log in here to read the desired article.
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2080 entries already.
Small- and medium-size European companies face the challenge of establishing global B2B activities in order to access relevant markets along the drug development value chain. YUMAB’s flexible business model for the development of fully human antibodies attracts corporations overseas and facilitates international partnerships.
The 9th edition of the European Biotechnology Science & Industry Guide once more offers an interesting cross-section of the European biotech scene.
Novartis has aquired all outstanding capital stock and paid US$310m upfront to Boston-based IFM Tre Inc., which commercialises three inflammasome blockers designed to treat chronic inflammatory diseases.
The European Medicines Agency has granted conditional approval for bluebird bio NV’s gene therapy Zynteglo (LentiGlobin BB305) to treat the rare disease transfusion-dependent ?-thalassemia at its first meeting in Amsterdam.
As resource-poor biotech start-ups are the drivers of innovation in the biotech sector, partnering with Big Pharma is essential to survive in a competitive environment. Yet, how to do most effectively? The most often held pharma partnering conference worldwide, euroPLX, provides a plausible answer.
Krakow-based Selvita S.A. has announced it will spin out its oncology unit this year resulting in two public companies, a CRO and a cancer therapeutics developer.
The CHF22.5m Series A financing round of the Swiss specialist for autoimmune diseases was led by Sofinnova Partners and New Enterprise Associates together with contributions of existing investors.
French liver disorder specialist Genfit SA has announced the pricing of its Nasdaq IPO of ADS and European private placement.